LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Lista de Ações・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Fechado

SetorSaúde

41.23 0.17

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

41.07

Máximo

41.77

Indicadores-chave
By Trading Economics
Rendimento	-547M -179M
Vendas	-515M 28M
Margem de lucro	-643.397
Funcionários	609
EBITDA	-546M -148M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+8.68% upside

Dividendos
By Dow Jones
Próximos Ganhos	25 de nov. de 2025

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	3.1B 5.4B
Abertura anterior	41.06
Fecho anterior	41.23

Sentimento de Notícias

By Acuity

16%

84%

15 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

11.5 / 12.23 Suporte e Resistência

Arrowhead Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de nov. de 2025, 17:45 UTC

Ganhos

Grandes Movimentos do Mercado

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 de nov. de 2025, 17:31 UTC

Ganhos

Grandes Movimentos do Mercado

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14 de nov. de 2025, 16:15 UTC

Grandes Movimentos do Mercado

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14 de nov. de 2025, 23:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 de nov. de 2025, 23:02 UTC

Conversa de Mercado

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 de nov. de 2025, 22:35 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 de nov. de 2025, 22:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 de nov. de 2025, 22:29 UTC

Ganhos

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 de nov. de 2025, 22:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 de nov. de 2025, 21:50 UTC

Conversa de Mercado

Ganhos

Tech, Media & Telecom Roundup: Market Talk

14 de nov. de 2025, 21:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 de nov. de 2025, 20:27 UTC

Conversa de Mercado

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 de nov. de 2025, 20:23 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 de nov. de 2025, 20:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 de nov. de 2025, 19:29 UTC

Conversa de Mercado

Ganhos

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 de nov. de 2025, 18:44 UTC

Conversa de Mercado

Ganhos

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 de nov. de 2025, 18:27 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

14 de nov. de 2025, 18:27 UTC

Conversa de Mercado

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 de nov. de 2025, 18:20 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 de nov. de 2025, 17:20 UTC

Conversa de Mercado

Ganhos

Auto & Transport Roundup: Market Talk

14 de nov. de 2025, 17:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

14 de nov. de 2025, 17:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

14 de nov. de 2025, 16:51 UTC

Conversa de Mercado

Starbucks Gets Holiday Sales Lift -- Market Talk

14 de nov. de 2025, 16:48 UTC

Conversa de Mercado

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 de nov. de 2025, 16:38 UTC

Conversa de Mercado

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14 de nov. de 2025, 16:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 de nov. de 2025, 16:28 UTC

Conversa de Mercado

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14 de nov. de 2025, 15:59 UTC

Conversa de Mercado

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14 de nov. de 2025, 15:06 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 de nov. de 2025, 15:06 UTC

Conversa de Mercado

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Comparação entre Pares

Variação de preço

Arrowhead Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

8.68% parte superior

Previsão para 12 meses

Média 44.71 USD 8.68%

Máximo 80 USD

Mínimo 17 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Arrowhead Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para Arrowhead Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

11.5 / 12.23Suporte e Resistência

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentimento

By Acuity

15 / 374 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.